Skip to main content

Kisqali Dosage

Generic name: RIBOCICLIB SUCCINATE 200mg
Dosage form: tablet, film coated
Drug class: CDK 4/6 inhibitors

Medically reviewed by Drugs.com. Last updated on Aug 24, 2023.

2.1 Dosing and Administration

The recommended dose of KISQALI is 600 mg (three 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food [see Clinical Pharmacology (12.3)].

When given with KISQALI, refer to the Full Prescribing Information for the recommended dose of the aromatase inhibitor being used.

When given with KISQALI, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter. Please refer to the Full Prescribing Information of fulvestrant.

Pre/perimenopausal women, or men, treated with the combination KISQALI plus an aromatase inhibitor should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards.

Men treated with the combination of KISQALI plus fulvestrant should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards.

Patients should take their dose of KISQALI at approximately the same time each day, preferably in the morning.

If the patient vomits after taking the dose, or misses a dose, no additional dose should be taken that day. The next prescribed dose should be taken at the usual time. KISQALI tablets should be swallowed whole (tablets should not be chewed, crushed or split prior to swallowing). No tablet should be ingested if it is broken, cracked, or otherwise not intact.

2.2 Dose Modifications

Dose Modifications for Adverse Reactions

The recommended dose modifications for adverse reactions are listed in Table 1.

Table 1: Recommended Dose Modification for Adverse Reactions
Level KISQALI
Dose Number of tablets
Starting dose 600 mg/day three 200 mg tablets
First dose reduction 400 mg/day two 200 mg tablets
Second dose reduction 200 mg/day* one 200 mg tablet
*If further dose reduction below 200 mg/day is required, discontinue the treatment.

Tables 2, 3, 4, 5, 6, and 7 summarize recommendations for dose interruption, reduction, or discontinuation of KISQALI in the management of specific adverse reactions. Dose modification of KISQALI is recommended based on individual safety and tolerability.

Table 2: Dose Modification and Management for Interstitial Lung Disease/Pneumonitis
Grade 1
(asymptomatic)		 Grade 2
(symptomatic)		 Grade 3 (severe symptomatic)
or 4 (life-threatening)
ILD/Pneumonitis
[see Warnings and
Precautions (5.1)]		 No dose interruption or adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated. Dose interruption until recovery
to Grade ≤ 1 then consider resuming KISQALI at the next lower dose level*.
If Grade 2 recurs, discontinue KISQALI.		 Discontinue KISQALI.
Abbreviation: ILD, interstitial lung disease.
Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
*An individualized benefit-risk assessment should be performed when considering resuming KISQALI.
Table 3: Dose Modification and Management for Cutaneous Adverse Reactions, Including SCARs
Grade 1
(< 10% body surface area (BSA) with active skin toxicity, no signs of systemic involvement)		 Grade 2
(10%-30% BSA with active skin toxicity, no signs of systemic involvement)		 Grade 3
(severe rash not responsive to medical management; > 30% BSA with active skin toxicity, signs of systemic involvement present; SJS*)		 Grade 4
(any % BSA associated with extensive superinfection, with IV antibiotics indicated; life threatening consequences; TEN**)
Cutaneous adverse reactions, including SCARs
[see Warnings and Precautions (5.2)]		 No dose adjustment is required.

Initiate appropriate medical therapy and monitor as clinically indicated.		 Interrupt KISQALI until the etiology of the reaction has been determined.

If the etiology is a SCAR, permanently discontinue KISQALI.

If the etiology is not a SCAR, interrupt dose until recovery to Grade ≤ 1, then resume KISQALI at same dose level.

If the cutaneous adverse reaction still recurs at Grade 3, resume KISQALI at the next lower dose level.		 Permanently discontinue KISQALI.
Abbreviations: BSA, body surface area; SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
*SJS (Grade 3 and 4) is defined as skin sloughing covering < 10% BSA and 10%-30% BSA, respectively, with associated signs (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment).
**TEN (Grade 4) is defined as skin sloughing covering ≥ 30% BSA with associated symptoms (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment).
Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Table 4: Dose Modification and Management for QT Prolongation
ECGs with QTcF* > 480 ms
[see Warnings and Precautions (5.3)]
  • Interrupt KISQALI treatment
  • If QTcF prolongation resolves to < 481 ms, resume treatment at the next lower dose level;
  • If QTcF ≥ 481 ms recurs, interrupt dose until QTcF resolves to < 481 ms; then resume KISQALI at next lower dose level.
ECGs with QTcF > 500 ms
[see Warnings and Precautions (5.3)]
  • Interrupt KISQALI treatment if QTcF greater than 500 ms
  • If QTcF prolongation resolves to < 481 ms, resume treatment at the next lower dose level.
Permanently discontinue KISQALI if QTcF interval prolongation is either greater than 500 ms or greater than 60 ms change from baseline AND associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia.
Electrocardiograms (ECGs) should be assessed prior to initiation of treatment.
Repeat ECGs at approximately Day 14 of the first cycle and at the beginning of the second cycle, and as clinically indicated.
In case of (QTcF) prolongation at any given time during treatment, more frequent ECG monitoring is recommended.
*QTcF = QT interval corrected by Fridericia’s formula.
Table 5: Dose Modification and Management for Hepatobiliary Toxicity
Grade 1
(> ULN – 3 x ULN)		 Grade 2
(> 3 to 5 x ULN)		 Grade 3
(> 5 to 20 x ULN)		 Grade 4
(> 20 x ULN)
AST and/or ALT elevations from baseline*, WITHOUT increase in total bilirubin above 2 x ULN
[see Warnings and Precautions (5.5)]		 No dose adjustment is required. Baseline* at < Grade 2:
Dose interruption until recovery to ≤ baseline grade, then resume KISQALI at same dose level. If Grade 2 recurs, resume KISQALI at next lower dose level.
-----------------------------
Baseline* at Grade 2:
No dose interruption.		 Dose interruption until recovery to ≤ baseline* grade, then resume at next lower dose level.
If Grade 3 recurs, discontinue KISQALI.		 Discontinue KISQALI.
Combined elevations in AST and/or ALT WITH total bilirubin increase, in the absence of cholestasis
[see Warnings and Precautions (5.5)]		 If patients develop ALT and/or AST > 3 x ULN along with total bilirubin > 2 x ULN irrespective of baseline grade, discontinue KISQALI.
Perform Liver Function Tests (LFTs) before initiating treatment with KISQALI.
Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.
If Grade ≥ 2 abnormalities are noted, more frequent monitoring is recommended.
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal.
*Baseline = prior to treatment initiation.
Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Table 6: Dose Modification and Management for Neutropenia
Grade 1 or 2
(ANC 1000/mm3 – < LLN)		 Grade 3
(ANC 500 - < 1000/mm3)		 Grade 3 febrile* neutropenia Grade 4
(ANC < 500/mm3)
Neutropenia
[see Warnings and Precautions (5.6)]		 No dose adjustment is required. Dose interruption until recovery to Grade ≤ 2.
Resume KISQALI at the same dose level.
If toxicity recurs at Grade 3, dose interruption until recovery, then resume KISQALI at the next lower dose level.		 Dose interruption until recovery of neutropenia to Grade ≤ 2. Resume KISQALI at the next lower dose level. Dose interruption until recovery to Grade ≤ 2.
Resume KISQALI at the next lower dose level.
Perform complete blood counts (CBCs) before initiating treatment with KISQALI.
Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.
Abbreviations: ANC, absolute neutrophil count; LLN, lower limit of normal.
*Grade 3 neutropenia with single episode of fever > 38.3°C (or) above 38°C for more than one hour and/or concurrent infection.
Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Table 7: Dose Modification and Management for Other Toxicities*
Grade 1 or 2 Grade 3 Grade 4
Other Toxicities No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated. Dose interruption until recovery to Grade ≤ 1 then resume KISQALI at same dose level.
If Grade 3 recurs, resume KISQALI at the next lower dose level.		 Discontinue KISQALI.
*Excluding interstitial lung disease (ILD)/pneumonitis, cutaneous adverse reactions, including severe cutaneous adverse reactions (SCARs), QT interval prolongation, hepatobiliary toxicity, and neutropenia.
Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Refer to the Full Prescribing Information for the coadministered aromatase inhibitor or fulvestrant for dose modification guidelines in the event of toxicity and other relevant safety information.

Dose Modification for Use with Strong CYP3A Inhibitors

Avoid concomitant use of KISQALI with strong CYP3A inhibitors and consider an alternative concomitant medication with less potential for CYP3A inhibition [see Drug Interactions (7.1)]. If a strong CYP3A inhibitor must be coadministered, reduce the KISQALI dose to 400 mg once daily. If the strong inhibitor is discontinued, change the KISQALI dose (after at least 5 half-lives of the strong CYP3A inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

Dose Modification for Hepatic Impairment

No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A). The recommended starting dose is 400 mg KISQALI once daily for patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

Review the Full Prescribing Information for the coadministered aromatase inhibitor or fulvestrant for dose modifications related to hepatic impairment.

Dose Modification for Renal Impairment

No dose adjustment is necessary in patients with mild or moderate renal impairment. The recommended starting dose is 200 mg KISQALI once daily for patients with severe renal impairment [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer